Soft tissue sarcomas (STSs) represent a rare, highly heterogeneous group of malignant tumors originating from non-epithelial extraskeletal tissues, including muscle, fat, fibrous tissue, vessels, and the peripheral nervous system. Accounted for by hundreds of distinct histological subtypes, diagnosing and managing soft tissue sarcomas requires a rigorous, systematic approach. Understanding their clinical presentation, anatomical distribution, and classification criteria is paramount for early diagnosis, optimal staging, and interdisciplinary management.
Anatomical Distribution & Histological Subtypes
Soft tissue sarcomas can arise anywhere in the body, but their distribution follows distinct anatomical patterns:
Extremities (60%): The lower extremity (particularly the thigh) is the most common site, followed by the upper extremity.
Trunk & Retroperitoneum (30%): Includes the retroperitoneal space, abdominal wall, and chest wall. Retroperitoneal sarcomas often remain asymptomatic until reaching significant dimensions.
Head & Neck (10%): Presents unique surgical challenges due to adjacent neurovascular and vital anatomical structures.
Predominant Histological Types
While over 50 histological subtypes exist, the vast majority of adult soft tissue sarcomas fall into key categories:
Undifferentiated Pleomorphic Sarcoma (UPS): Formerly known as Malignant Fibrous Histiocytoma (MFH), this is the most common subtype in older adults, typically presenting in the deep soft tissues of the limbs.
Liposarcoma: Originates from adipocytes; subtypes range from well-differentiated/atypical lipomatous tumors to aggressive dedifferentiated, myxoid, and pleomorphic forms.
Leiomyosarcoma: Smooth muscle tumors commonly found in the retroperitoneum, uterus, and large blood vessels.
Synovial Sarcoma: Often occurring in young adults near large joints (though rarely originating within the joint cavity itself), harboring a characteristic $t(X;18)$ translocation.
Rhabdomyosarcoma: The most prevalent soft tissue sarcoma in children and adolescents, characterized by skeletal muscle differentiation.
Clinical Presentation & Diagnostic Red Flags
Most soft tissue sarcomas manifest as an asymptomatic, slow-growing, painless mass. Pain usually develops late due to infiltration or compression of adjacent nerves, periosteum, or vascular structures.
Diagnostic "Red Flag" Criteria
Any soft tissue mass exhibiting the following features must be considered malignant until proven otherwise:
Size: Greater than $5\text{ cm}$ in diameter.
Depth: Deep to the superficial fascia.
Growth: Rapidly increasing in size.
Recurrence: Painful or recurrent mass following previous excision.
Clinical Pearl: Never perform an open excisional biopsy on an unexplained soft tissue mass meeting red flag criteria before obtaining staging imaging. Inappropriate primary excision severely compromises definitive surgical margins and patient prognosis.
Staging & Risk Stratification
The American Joint Committee on Cancer (AJCC) TNM staging system for soft tissue sarcomas integrates four crucial parameters:
T (Primary Tumor Size): Categorized by dimensions ($\le 5\text{ cm}$, $5\text{--}10\text{ cm}$, $10\text{--}15\text{ cm}$, $>15\text{ cm}$).
N (Regional Lymph Nodes): N0 (no regional lymph node metastasis) vs. N1 (regional lymph node metastasis present). Node involvement is overall rare ($<5\%$), except in specific subtypes such as clear cell sarcoma, rhabdomyosarcoma, epithelioid sarcoma, and synovial sarcoma.
M (Distant Metastasis): M0 (no distant metastasis) vs. M1 (distant metastasis present, most commonly to the lungs).
G (Histological Grade): French Federation of Cancer Centers Sarcoma Group (FNCLCC) grading system based on tumor differentiation, mitotic count, and necrosis extent.
| Histological Grade | Differentiation Score | Mitotic Count Score | Necrosis Score |
| Grade 1 (Low) | Resembles normal tissue (1) | Low ($<10 / 10\text{ HPF}$) (1) | None (0) |
| Grade 2 (Intermediate) | Defined histological type (2) | Moderate ($10\text{--}19 / 10\text{ HPF}$) (2) | $<50\%$ tumor necrosis (1) |
| Grade 3 (High) | Undifferentiated (3) | High ($\ge 20 / 10\text{ HPF}$) (3) | $\ge 50\%$ tumor necrosis (2) |
Diagnostic Workup Protocol
Magnetic Resonance Imaging (MRI): The gold standard imaging modality for extremity and pelvic soft tissue lesions. Provides superior soft tissue contrast to evaluate compartment involvement and neurovascular proximity.
Computed Tomography (CT): Preferred imaging modality for retroperitoneal and visceral lesions, as well as mandatory baseline staging of the chest to rule out pulmonary metastases.
Core Needle Biopsy (CNB): The preferred diagnostic tissue sampling technique. Must be planned in consultation with the operating orthopedic/surgical oncologist so the biopsy tract can be excised en bloc during definitive surgery.